Discontinued — last reported Q4 '25
Cash & Equivalents
Current AssetsJohnson & Johnson Cash & Equivalents decreased by 1.9% to $18.23B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 8.8%, from $19.98B to $18.23B. Over 3 years (FY 2021 to FY 2024), Cash & Equivalents shows an upward trend with a 11.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase signals improved liquidity and the ability to fund operations or acquisitions without debt; a decrease may indicate heavy capital expenditure or shareholder returns.
Detailed definition
Represents the most liquid assets on the balance sheet, including physical currency and short-term instruments with matu...
Peer comparison
Peer tech giants like Alphabet or Apple maintain massive cash reserves to navigate market volatility and fund R&D.
cash_and_equivalentsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $12.67B | $14.33B | $17.60B | $14.49B | $10.46B | $10.98B | $14.13B | $19.17B | $19.73B | $21.86B | $25.47B | $24.88B | $19.98B | $24.11B | $38.47B | $18.58B | $18.23B |
| QoQ Change | — | +13.1% | +22.8% | -17.7% | -27.8% | +5.0% | +28.6% | +35.7% | +2.9% | +10.8% | +16.5% | -2.3% | -19.7% | +20.6% | +59.6% | -51.7% | -1.9% |
| YoY Change | — | — | — | — | -17.4% | -23.4% | -19.8% | +83.2% | +79.6% | +54.7% | — | +29.8% | +1.3% | +10.3% | +51.0% | -25.3% | -8.8% |
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's cash & equivalents?
- Johnson & Johnson (JNJ) reported cash & equivalents of $18.23B in Q3 2025.
- How has Johnson & Johnson's cash & equivalents changed year-over-year?
- Johnson & Johnson's cash & equivalents decreased by 8.8% year-over-year, from $19.98B to $18.23B.
- What is the long-term trend for Johnson & Johnson's cash & equivalents?
- Over 3 years (2021 to 2024), Johnson & Johnson's cash & equivalents has grown at a 11.0% compound annual growth rate (CAGR), from $17.60B to $24.11B.
- What does cash & equivalents mean?
- Money in the bank and investments that can be turned into cash almost instantly.